Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Short Interest Update

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totaling 28,845 shares, a decline of 28.4% from the December 31st total of 40,313 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average trading volume of 47,850 shares, the short-interest ratio is currently 0.6 days. Based on an average trading volume of 47,850 shares, the short-interest ratio is currently 0.6 days. Approximately 0.1% of the company’s shares are short sold.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on NBTX shares. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. Leerink Partners reiterated an “outperform” rating on shares of Nanobiotix in a research report on Tuesday, November 25th. HC Wainwright restated a “buy” rating on shares of Nanobiotix in a report on Tuesday, November 4th. Finally, Wall Street Zen raised shares of Nanobiotix to a “hold” rating in a research note on Saturday, October 25th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $11.00.

Nanobiotix Stock Performance

Shares of Nanobiotix stock traded up $0.37 during trading hours on Monday, reaching $21.37. The stock had a trading volume of 35,018 shares, compared to its average volume of 26,889. Nanobiotix has a 1 year low of $2.95 and a 1 year high of $30.35. The firm has a 50 day simple moving average of $21.59 and a two-hundred day simple moving average of $17.03.

Institutional Investors Weigh In On Nanobiotix

An institutional investor recently bought a new position in Nanobiotix stock. Optiver Holding B.V. acquired a new position in Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 5,356 shares of the company’s stock, valued at approximately $101,000. Institutional investors own 38.81% of the company’s stock.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.